SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equilis Prequenza suspension for injection for horses

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (1 ml) contains:

Active substances:

Equine influenza virus strains:	
A/equine-2/South Africa/4/03	50 AU[1]
A/equine-2/Newmarket/2/93	50 AU

[1] Antigenic units

Adjuvants:

Iscom-Matrix containing:	
Purified Saponin	375 µg
Cholesterol	125 µg
Phosphatidylcholine	62.5 µg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Clear opalescent suspension.

4. CLINICAL PARTICULARS

4.1 Target species

Horses.

4.2 Indications for use, specifying the target species

Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.

Onset of immunity: 2 weeks after the primary vaccination course
Duration of immunity: 5 months after the primary vaccination course
1 year after the first revaccination

4.3 Contraindications

None.

4.4 Special warnings for each target species

Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.

4.5 Special precautions for use

Special precautions for use in animals:
Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:
Not applicable.

Other precautions:
Not applicable

4.6 Adverse reactions (frequency and seriousness)

Horses:

Rare (1 to 10 animals / 10,000 animals treated):	Injection site swelling[1], Injection site pain[2].
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Fever[3], Lethargy[3], Inappetence[3], Hypersensitivity reaction[4].

[1] A diffuse hard or soft swelling (max. diameter 5 cm), regressing within 2 days. A local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur in very rare cases.
[2] Pain at the injection site may result in temporary functional discomfort (stiffness).
[3] Fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances.
[4] Including anaphylaxis (sometimes fatal). If such a reaction occurs, appropriate treatment should be administered without delay.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.

4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
Can be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amount(s) to be administered and administration route

Intramuscular use.

Allow the vaccine to reach room temperature before use.

Vaccination schedule:
Primary vaccination course
Administer one dose (1 ml) by intramuscular injection according to the following schedule:

- Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later.

Revaccination
It is recommended that a single booster dose should only be administered to horses that have already received a primary vaccination course using vaccines that contain the same types of equine influenza virus included in this vaccine. A primary vaccination course may be considered necessary in horses that have not been suitably primed.

The first revaccination (third dose) is given 5 months after the primary vaccination course. This revaccination results in immunity to equine influenza lasting at least 12 months.

The second revaccination is given 12 months after the first revaccination.

The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).



In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Following the administration of a double dose of vaccine, no side-effects other than those described under section 4.6 have been observed except for some depression at the day of vaccination.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunologicals for *Equidae*, inactivated viral vaccines.

ATCvet code: QI05AA01.

To stimulate active immunity against Equine influenza in horses.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Phosphate buffer

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.

6.5 Nature and composition of immediate packaging

Type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Type I glass pre-filled syringes of 1 ml (1 dose), containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.

Pack sizes:
Cardboard box with 10 glass vials of 1 ml (1 dose).
Cardboard box with 1, 5 or 10 pre-filled syringes of 1 ml (1 dose) with needles.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited
Walton Manor, Walton
Milton Keynes
Buckinghamshire
MK7 7AJ

8. MARKETING AUTHORISATION NUMBER

Vm 01708/5032

9. DATE OF FIRST AUTHORISATION

08 July 2005

10. DATE OF REVISION OF THE TEXT

December 2023

11. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.
Find more product information by searching for the ‘Product Information Database’ or ‘PID’ on www.gov.uk.

Approved 18 December 2023